Present Technology

- Stem Cell Therapy (hPSC-CMs):Â Transplanted cells fire independently, triggering dangerous ventricular tachycardia instead of integrating with existing heart rhythm.
Â
- Direct reprogramming (GMT): Fibroblast DNA is tightly packed, blocking the transcription factors from accessing them. Many cells only partially convert, producing electrically unstable intermediate cells that raise arrhythmia risk.
Â
- Viral delivery vectors: Modified viruses can unintentionally activate genes in healthy cells or disrupt important DNA regions, heightening the risk of abnormal growth.
Â
- No mechanical awareness:Â Existing technologies ignore the unique mechanical stiffness of the infarct border zone, missing a critical biological signal that could improve targeting precision.

Key limitations
Poor cell retention
​
​
 Arrhythmia risk
​
​
 Incomplete reprogramming
​
​
 Viral safety concerns
​
Â
Lack of mechanical targeting
Breakthroughs Needed
SYNCARDIA requires advances in precision delivery, timing, and control.
​
-
Lipid nanoparticles must respond only to focused ultrasound in heart tissue, enabling non-invasive, localized delivery without off-target activation.
​
-
Epigenetic priming proteins must degrade with exact timing after reperfusion, preventing prolonged genomic instability.
​
-
Synthetic genetic circuits must achieve zero-leak activation, ensuring reprogramming occurs only in injured cardiac fibroblasts.
​
Â
These breakthroughs allow SYNCARDIA to safely regenerate contractile, electrically synchronized heart tissue instead of just replacing scars.
